MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of marketable...
$596,288K
Proceeds from issuance of
stock from employee...
$2,388K
Net cash provided by
(used in) investing...
$209,072K
Net cash provided by
financing activities
$2,388K
Canceled cashflow
$387,216K
Net increase
(decrease) in cash and cash...
$515K
Canceled cashflow
$210,945K
Purchases of marketable
securities
$384,502K
Acquisition of property and
equipment
$2,714K
Stock-based compensation
expense
$36,217K
Accounts payable and
accrued expenses
$11,031K
Prepaid and other
current assets
-$8,706K
Depreciation and
amortization
$3,380K
Loss on disposal of
assets
-$12K
Net cash used in
operating activities
-$210,945K
Canceled cashflow
$59,346K
Net loss
-$258,757K
Amortization and premium of
marketable securities, net
$5,855K
Other assets
$3,611K
Accounts and other
receivables
$1,315K
Other liabilities
-$753K
Back
Back
Cash Flow
source: myfinsight.com
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)